Photo of Bruce A. Chabner,  MD

Bruce A. Chabner, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-3200
Fax: (617) 643-2683

Bruce A. Chabner, MD

Massachusetts General Hospital


  • Professor, Medicine, Harvard Medical School
  • Director of Clinical Research, MGH Cancer Center, Massachusetts General Hospital



  • Member, Clinical Science Coordinating Committee

Research Abstract

Major interest is in the clinical testing, pharmaco-kinetics, and biochemical pharacology of new anticancer drugs, particulary natural products and signal transdution inhibitors.


Powered by Harvard Catalyst
  • Gainor JF, Chabner BA. Ponatinib: Accelerated Disapproval. Oncologist 2015. PubMed
  • Percac-Lima S, Cronin PR, Ryan DP, Chabner BA, Daly EA, Kimball AB. Patient navigation based on predictive modeling decreases no-show rates in cancer care. Cancer 2015. PubMed
  • Chabner BA. Defining a New Role for the National Cancer Institute Cooperative Groups: More Science, Fewer Trials. Oncologist 2014. PubMed
  • Efstathiou JA, Bvochora-Nsingo M, Gierga DP, Alphonse Kayembe MK, Mmalane M, Russell AH, Paly JJ, Brown C, Musimar Z, Abramson JS, Bruce KA, Karumekayi T, Clayman R, Hodgeman R, Kasese J, Makufa R, Bigger E, Suneja G, Busse PM, Randall TC, Chabner BA, Dryden-Peterson S. Addressing the Growing Cancer Burden in the Wake of the AIDS Epidemic in Botswana: The BOTSOGO Collaborative Partnership. Int J Radiat Oncol Biol Phys 2014; 89:468-75. PubMed
  • Chabner BA. Approval after phase I: ceritinib runs the three-minute mile. Oncologist 2014; 19:577-8. PubMed
  • Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res 2014; 20:2587-94. PubMed
  • Chabner BA. Effective double whammy targets DNA synthesis in leukemia. J Exp Med 2014; 211:384. PubMed
  • Chabner BA, Ellisen LW, Iafrate AJ. Personalized medicine: hype or reality. Oncologist 2013; 18:640-3. PubMed
  • Percac-Lima S, Benner CS, Lui R, Aldrich LS, Oo SA, Regan N, Chabner BA. The impact of a culturally tailored patient navigator program on cervical cancer prevention in latina women. J Womens Health (Larchmt) 2013; 22:426-31. PubMed
  • Fojo AT, Bates SE, Chabner BA. Clinical trial results: Sharing results, speeding discoveries. Oncologist 2013; 18:779. PubMed
  • Chabner BA, Efstathiou J, Dryden-Peterson S, . Cancer in Botswana: the second wave of AIDS in Sub-Saharan Africa. Oncologist 2013; 18:777-8. PubMed
  • Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N Engl J Med 2012; 367:2150-3. PubMed
  • Raj A, Ko N, Battaglia TA, Chabner BA, Moy B. Patient navigation for underserved patients diagnosed with breast cancer. Oncologist 2012; 17:1027-31. PubMed
  • Chabner BA. That old devil moon. Oncologist 2012; 17:1349-50. PubMed
  • Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011; 364:1087-9. PubMed
  • Murphy JP, Chabner BA. Reflections on the knife edge. Oncologist 2011; 16:257-9. PubMed
  • Donelan K, Mailhot JR, Dutwin D, Barnicle K, Oo SA, Hobrecker K, Percac-Lima S, Chabner BA. Patient Perspectives of Clinical Care and Patient Navigation in Follow-up of Abnormal Mammography. J Gen Intern Med 2010. PubMed
  • Chabner BA. New results will change the paradigm for phase I trials and drug approval. Oncologist 2010; 15:1023-5. PubMed
  • Chabner BA. About Eli. Oncologist 2010; 15:329-31. PubMed
  • Chabner BA. Academia-pharma intersect: providing a broader perspective on drug development synergies between academia and industry. Oncologist 2010; 15:1-2. PubMed
  • Chong CR, Chabner BA. Mysterious metformin. Oncologist 2009; 14:1178-81. PubMed
  • Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459-68. PubMed
  • Donelan K,Hobrecker K,Schapira L,Mailhot JR,Goulart BH,Chabner BA. Medical interpreter knowledge of cancer and cancer clinical trials. Cancer 2009; 115:3283-92. PubMed
  • Chabner BA. Obituary. Cancer Sci 2009; 100:565-6. PubMed
  • Chabner BA. Ghost writers in the sky. Oncologist 2009; 14:199-200. PubMed
  • Chabner BA. The National Cancer Institute and its Director: worthy of our full support. Oncologist 2009; 14:108-9. PubMed
  • Schapira L,Gordon-Rowe L,Martignetti R,Washington D,Bartholomay M,Greenberg D,Lathan C,LaFrancesca J,Lynch T,Chabner B. Racism in the chemotherapy infusion unit: a nurse's story. Oncologist 2008; 13:1177-80. PubMed
  • Chabner BA. Dr. Joseph R. Bertino: a reflection. Oncologist 2008; 13:1034-5. PubMed
  • Chabner BA. Preserving the sacred bond: an audit must be performed. Oncologist 2008; 13:922. PubMed
  • Curt GA,Chabner BA. One in five cancer clinical trials is published: a terrible symptom--what's the diagnosis? Oncologist 2008; 13:923-4. PubMed
  • Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. J Clin Oncol 2008; 26:2717-24. PubMed
  • Chabner BA. Smoke, then Fire: Lung Cancer Screening Studies Under Further Scrutiny. Oncologist 2008; 13:348-9. PubMed
  • Chabner BA. Conflict of interest: in the eye of the beholder? Oncologist 2008; 13:212-3. PubMed
  • Chabner B. Advances and challenges in the use of biomarkers in clinical trials. Clin Adv Hematol Oncol 2008; 6:42-3. PubMed
  • Novina CD, Chabner BA. RNA-Directed Therapy: The Next Step in the miRNA Revolution. Oncologist 2008; 13:1-3. PubMed
  • Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007; 13:6719-26. PubMed
  • Chabner BA, Ratain MJ. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control Clin Cancer Res 2007; 13:6540. PubMed
  • Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res 2007; 13:5232-7. PubMed
  • Chabner BA. Orange alert for oncologists. Oncologist 2007; 12:902-3. PubMed
  • Chabner B. Phase II cancer trials: out of control? Clin Cancer Res 2007; 13:2307-8. PubMed
  • Penson RT, Kyriakou H, Zuckerman D, Chabner BA, Lynch TJ. Teams: communication in multidisciplinary care. Oncologist 2006; 11:520-6. PubMed
  • Abel GA, Penson RT, Joffe S, Schapira L, Chabner BA, Lynch TJ. Direct-to-consumer advertising in oncology. Oncologist 2006; 11:217-26. PubMed
  • Wolpin BM, Chabner BA, Lynch TJ, Penson RT. Learning to cope: how far is too close? Oncologist 2005; 10:449-56. PubMed